http://orcid.org/0000-0001-8470-394X
References
- Weis T, Marini B, Nachar V, et al. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma. 2020;61;1126–1132.
- McCune JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health Syst Pharm. 1997;54(15):1755–1758.
- Whitelaw D, Cowan D, Cassidy F, et al. Clinical experience with vincristine. Cancer Chemother Reports. 1962;30:13–20.
- VinCRIStine Sulfate Package insert [Internet]. [cited 2020 Jan 2]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=4653
- Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295–1306.
- Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;1(2):146–153.
- Groninger E, Meeuwsen-De Boer T, Koopmans P, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2002;52(1):113–118.
- Madsen ML, Due H, Ejskjaer N, et al. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019;84(3):471–485.
- Frost B-M, Lönnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2007;92(5):551–557.
- van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol. 2017;114:114–130.
- Watkins SM, Griffin JP. High incidence of vincristine-induced neuropathy in lymphomas. Br. Med. J. 1978;1(6113):610–612.
- Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. J Am Med Assoc. 2015;313(8):815–823.
- Folmer Y, Schneider M, Blum HE, et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007;14(11):875–884.
- Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731–741.
- Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–367.
- Skiles JL, Chiang CW, Li CH, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. 2018;65(3):e26854.
- Berenson MP. Recovery after inadvertent massive overdosage of vincristine (NSC-67574). Cancer Chemother Reports. 1971;55:525–526.
- Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973;33(6):1258–1264.
- Haim N, Barron SA, Robinson E. Muscle cramps associated with vincristine therapy. Acta Oncol. 1991;30(6):707–711.
- Hagemeister F, Rodriguez MA, Deitcher SR, et al. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphoma. Br J Haematol. 2013;162(5):631–638.